Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Operating Expenses: 2020-2024

Historic Other Operating Expenses for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $117.7 million.

  • Apellis Pharmaceuticals' Other Operating Expenses fell 26.90% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.4 million, marking a year-over-year increase of 17.15%. This contributed to the annual value of $117.7 million for FY2024, which is 101.20% up from last year.
  • As of FY2024, Apellis Pharmaceuticals' Other Operating Expenses stood at $117.7 million, which was up 101.20% from $58.5 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Other Operating Expenses ranged from a high of $117.7 million in FY2024 and a low of $5.6 million during FY2022.
  • Over the past 3 years, Apellis Pharmaceuticals' median Other Operating Expenses value was $58.5 million (recorded in 2023), while the average stood at $60.6 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Other Operating Expenses crashed by 92.97% in 2022 and then surged by 938.15% in 2023.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Other Operating Expenses stood at $25.1 million in 2020, then skyrocketed by 220.16% to $80.2 million in 2021, then plummeted by 92.97% to $5.6 million in 2022, then spiked by 938.15% to $58.5 million in 2023, then spiked by 101.20% to $117.7 million in 2024.